Wet Lab Testing of AI-Designed Drugs and Proteins

AI is revolutionizing the field by enabling the de novo design of drug molecules that specifically target desired proteins, as well as optimizing the binding characteristics of lead compounds.

Objective wet-lab testing data to validate artificial intelligence (AI) designed drugs

Accelerate Drug Development with SPOC

The SPOC platform is a powerful in vitro tool to rapidly evaluate these in silico designed drug molecules, providing real-world data on drug-protein interactions. This facilitates multiple iterative design and testing cycles, crucial for developing drugs with optimal therapeutic effects. 

AI-Driven Drug Design

AI drug designers can now leverage the SPOC platform to simultaneously generate kinetic parameters (such as ka, kd, affinity KD, half-life t1/2) for thousands of drug-target interactions in a single assay. This capability enables the efficient down-selection of promising lead molecules and their iterative improvement, accelerating the development of best-in-class drugs.

Synthetic biology: purpose designed proteins

We are in the early stages of AI-driven drug design. Current AI models are primarily trained on limited datasets of known drug-protein interactions, which restricts their predictive accuracy.

Given the vast and complex landscape of potential drug-target interactions, the effectiveness of these AI models is closely tied to the scale and quality of the training data.





The SPOC platform's kinetic screening capabilities provide deep characterization data using surface plasmon resonance (SPR) real-time biosensing, which is not achievable with current phage and yeast display technologies. SPOC enables large-scale, whole-proteome screening, generating tens of thousands of kinetic data points at a fraction of the cost compared to traditional recombinant protein SPR workflows.

Additionally, we are advancing our capabilities to enable N x M screening with SPOC using MALDI-TOF mass spectrometry profiling. This approach will generate millions of drug-protein interaction data points in a single run, complementing the SPR kinetic deep characterization data, and significantly enhancing the depth and breadth of AI model training datasets.

Synthetic biology: purpose designed proteins

Purpose-designed proteins represent the next frontier in biotechnology, whether inspired by natural proteins or designed entirely from scratch. Imagine novel proteins or enzymes engineered to more effectively capture carbon for climate change mitigation, accelerate the breakdown of plastics for faster biodegradation, catalyze the low-energy splitting of water to produce hydrogen for fuel cells, or synthesize key ingredients on demand for various industries, such as cosmetics. Innovators around the world are pioneering these exciting new approaches.

However, novel proteins produced through synthetic biology often face challenges such as poor expression or toxicity in cell-based systems. The SPOC platform addresses these issues with its cell-free production method, enabling the production and screening of virtually any novel protein design, a library of protein designs tested at once. It also supports downstream kinetic affinity screening with binding partners to quickly assess functionality. In the future, we plan to incorporate protein activity testing assays on the SPOC platform to further expand its capabilities.

The Sensor-Integrated Proteome on Chip (SPOC®) technology revolutionized our research. The precise proteomic data we obtained has significantly accelerated our drug development process, leading to more effective treatments. This platform is a game-changer for personalized medicine.”

Dr. Emily Reynolds

Lead Scientist, Genomics Research Institute

For more information on the SPOC platform, get in touch:

Contact Us

1600 Adams Drive

Suite236



Menlo Park, CA 94025

7201 E Henkel Way

Suite 285



Scottsdale, AZ 85255

480-219-9506

Privacy & Conditions

All rights reserved © 2024